# Innate Immunity Stimulation Via TLR9 in Early AD

> **NCT05606341** · PHASE1 · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 18 (estimated)

## Conditions studied

- Mild Cognitive Impairment
- Alzheimer Dementia

## Interventions

- **DRUG:** CpG1018
- **DRUG:** CpG1018
- **DRUG:** CpG1018
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05606341
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-13
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05606341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05606341, "Innate Immunity Stimulation Via TLR9 in Early AD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05606341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*